Delayed hospitalisation for heart failure after transcatheter repair or medical treatment for secondary mitral regurgitation: a landmark analysis of the MITRA-FR trial
| العنوان: | Delayed hospitalisation for heart failure after transcatheter repair or medical treatment for secondary mitral regurgitation: a landmark analysis of the MITRA-FR trial |
|---|---|
| المؤلفون: | Guillaume Leurent, Vincent Auffret, Erwan Donal, Hervé Corbineau, Daniel Grinberg, Guillaume Bonnet, Pierre-Yves Leroux, Patrice Guérin, Fabrice Wautot, Thierry Lefèvre, David Messika-Zeitoun, Bernard Iung, Xavier Armoiry, Jean-Noël Trochu, Florent Boutitie, Jean-François Obadia |
| المساهمون: | Laboratoire Traitement du Signal et de l'Image (LTSI), Université de Rennes (UR)-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Pontchaillou [Rennes], Hospices Civils de Lyon (HCL), Hôpital Louis Pradel [CHU - HCL], CHU Marseille, Médipôle Lyon-Villeurbanne, Centre hospitalier universitaire de Nantes (CHU Nantes), Centre Cardio-Thoracique de Monaco (CCTM), Hôpital Privé Jacques Cartier [Massy], University of Ottawa [Ottawa], Laboratoire de Recherche Vasculaire Translationnelle (LVTS (UMR_S_1148 / U1148)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité)-Université Sorbonne Paris Nord, Matériaux, ingénierie et science [Villeurbanne] (MATEIS), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National des Sciences Appliquées de Lyon (INSA Lyon), Université de Lyon-Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Centre National de la Recherche Scientifique (CNRS), Laboratoire de Biométrie et Biologie Evolutive - UMR 5558 (LBBE), Université de Lyon-Université de Lyon-Institut National de Recherche en Informatique et en Automatique (Inria)-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS), The MITRA-FR trial was financed by an academic grant from the French Ministry of Health., Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPC)-Université Sorbonne Paris Nord |
| المصدر: | EuroIntervention EuroIntervention, 2022, ⟨10.4244/EIJ-D-21-00846⟩ EuroIntervention, EuroPCR, 2022, ⟨10.4244/EIJ-D-21-00846⟩ |
| بيانات النشر: | HAL CCSD, 2022. |
| سنة النشر: | 2022 |
| مصطلحات موضوعية: | Heart Failure, Heart Valve Prosthesis Implantation, Hospitalization, Cardiac Catheterization, Treatment Outcome, [SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, Humans, Mitral Valve Insufficiency, [SDV.IB]Life Sciences [q-bio]/Bioengineering, Cardiology and Cardiovascular Medicine |
| الوصف: | International audience; BACKGROUND: In the MITRA-FR trial, transcatheter mitral valve repair (TMVR) was not associated with a 2-year clinical benefit in patients with secondary mitral regurgitation (SMR). AIMS: This landmark analysis aimed at investigating a potential reduction of the hospitalisation rate for heart failure (HF) between 12 and 24 months after inclusion in the MITRA-FR trial in patients randomised to the intervention group (TMVR with the MitraClip device), as compared with patients randomised to the control group (guideline-directed medical therapy [GDMT]). METHODS: The MITRA-FR trial randomised 307 patients with SMR for TMVR on top of GDMT (TMVR group; n=152) or for GDMT alone (control group; n=155). We conducted a 12-month landmark analysis in surviving patients who were not hospitalised for HF within the first 12 months of follow-up. The primary endpoint was the 1-year cumulative number of HF hospitalisations. RESULTS: A total of 140 patients (TMVR group: 67; GDMT group: 73) were selected for this landmark analysis with similar characteristics at inclusion in the trial. The primary endpoint was 28 events per 100 patient-years in the TMVR group, as compared with 60 events per 100 patient-years in the GDMT group (hazard ratio [HR] 0.46, 95% confidence interval [CI]: 0.20-1.02; p=0.057). CONCLUSIONS: In this landmark analysis of the MITRA-FR trial, the cumulative rate of HF hospitalisation between 12 and 24 months among patients treated with TMVR on top of GDMT was approximately half as many as those of patients treated with GDMT alone, a difference which did not reach statistical significance in the setting of a low number of events. |
| اللغة: | English |
| تدمد: | 1774-024X |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ff6b9a285211645ddfa279561f9ff2f1Test https://hal.science/hal-03689834Test |
| رقم الانضمام: | edsair.doi.dedup.....ff6b9a285211645ddfa279561f9ff2f1 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 1774024X |
|---|